Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. April 2018 08:00 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma

MADISON, Wis., April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
27. März 2018 08:00 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles

MADISON, Wis., March 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
21. März 2018 16:10 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Reports 2017 Financial Results and Provides a Corporate Update

MADISON, Wis., March 21, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
19. März 2018 08:05 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma

MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
19. März 2018 08:00 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018

MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
15. März 2018 08:00 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131

MADISON, Wis., March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
06. März 2018 08:00 ET | Quelle: Cellectar Biosciences, Inc.

Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology

MADISON, Wis., March 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
05. März 2018 08:00 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at Upcoming March Conferences

MADISON, Wis., March 05, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
08. Februar 2018 08:15 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference

MADISON, Wis., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
07. Februar 2018 08:15 ET | Quelle: Cellectar Biosciences, Inc.

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

MADISON, Wis., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...

Vorherige Seite

Nächste Seite